Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | F2R | P25116 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9282683 | 0.85 | GAA (0.60) | GAAALOX5PTGS1PTGS2LMNA | |
| SCHEMBL18083571 | 0.81 | ALOX5 (0.53) | GAAALOX5PTGS1PTGS2LMNA | |
| SCHEMBL724655 | 0.79 | PTGS1 (0.51) | GAAALOX5PTGS1PTGS2LMNA | |
| SCHEMBL1928189 | 0.78 | LMNA (0.61) | GAAALOX5PTGS1PTGS2LMNA | |
| SCHEMBL6960979 | 0.78 | GAA (0.61) | GAAALOX5PTGS1PTGS2LMNA | |
| SCHEMBL10414409 | 0.77 | ALOX5 (0.55) | GAAALOX5PTGS1PTGS2LMNA | |
| SCHEMBL1189097 | 0.77 | ALOX5 (0.55) | GAAALOX5PTGS1PTGS2LMNA | |
| SCHEMBL10786189 | 0.77 | ALOX5 (0.55) | GAAALOX5PTGS1PTGS2LMNA | |
| SCHEMBL2481839 | 0.77 | ALOX5 (0.55) | GAAALOX5PTGS1PTGS2LMNA | |
| SCHEMBL10786179 | 0.77 | ALOX5 (0.55) | GAAALOX5PTGS1PTGS2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751084-B1 | PYRIMIDINE CARBOXAMIDE DERIVATIVES | EUDIS BIOTECH LLC (CN) | 2016-09-21 | — | — | EP | disclosed |
| US-9249107-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249107-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249107-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150087665-A1 | Pyrimidine carboxamide derivatives | Maehr, Hubert (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150087665-A1 | Pyrimidine carboxamide derivatives | Maehr, Hubert (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150087665-A1 | Pyrimidine carboxamide derivatives | Maehr, Hubert (US) | 2015-03-26 | — | — | US | disclosed |
| EP-2751084-A1 | PYRIMIDINE CARBOXAMIDE DERIVATIVES | Apac Pharmaceutical LLC. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-8580805-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580805-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580805-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2013-11-12 | — | — | US | disclosed |
| WO-2013032522-A1 | PYRIMIDINE CARBOXAMIDE DERIVATIVES | APAC PHARMACEUTICAL LLC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20120053346-A1 | Pyrimidine Carboxamide Derivatives | MAEHR HUBERT (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053346-A1 | Pyrimidine Carboxamide Derivatives | MAEHR HUBERT (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053346-A1 | Pyrimidine Carboxamide Derivatives | NOD1, IL1B, IRAK1 | GAA 3313/4885ALOX5 560/4885PTGS1 22/4885 |
| US-20150087665-A1 | Pyrimidine carboxamide derivatives | NOD1, IL1B, IRAK1 | GAA 3313/4885ALOX5 560/4885PTGS1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.